Seer, Inc. (SEER)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 6 | 15 | 15 | 14 | 16 | 14 | 16 |
| Operating profit | $m | -78 | -71 | ||||||
| Net profit | $m | -33 | -71 | -93 | -86 | -87 | -74 | -68 | -61 |
| EPS reported | $ | -1.28 | -1.22 | ||||||
| Operating cashflow per share | $ | -0.77 | -0.79 | ||||||
| Capex per share | $ | 0.03 | 0.02 | ||||||
| FCF per share | $ | -0.80 | -0.80 | ||||||
| Free cash flow | $m | -46 | -44 | ||||||
| Net debt | $m | -165 | -153 | ||||||
| Book value equity | $m | 259 | 226 | ||||||
| Book value per share | $ | 4.51 | 4.09 | ||||||
| Number of shares | m | 57.45 | 55.16 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.41 | 0.47 | ||||||
| P/S LTM | x | 6.52 | 7.59 | ||||||
| P/FCF LTM | x | -2.27 | -2.38 | ||||||
| EV/EBITDA LTM | x | -1.13 | -1.27 | ||||||
| EV/Sales LTM | x | 5.06 | 7.99 | ||||||
| Earnings Yield LTM | % | -70.01% | -59.23% | ||||||
| FCF Yield | % | -43.99% | -42.07% | ||||||
| Quality | |||||||||
| ROE | % | -28.38% | -27.23% | ||||||
| ROIC | % | -27.56% | -28.55% | ||||||
| Operating margin | % | -4.84% | -5.11% | ||||||
| Gross margin | % | +49.67% | +46.31% | ||||||
| FCF/Sales | % | -286.90% | -319.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +15.57% | -0.70% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.96 | -1.98 | ||||||
| Net Debt/EBITDA | x | 0.33 | 0.06 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +20.05% | 0.00% | ||||||
| Net debt/Equity | x | -0.64 | -0.68 | ||||||
| Gross debt/equity | x | 0.09 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free